Almotriptan
Selective Serotonin (5ht1) Agonists
- Drug class
- Selective Serotonin (5ht1) Agonists
- Availability
- See label
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 15
Overview
Almotriptan is an active pharmaceutical ingredient in the Selective Serotonin (5ht1) Agonists group (N02CC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 9 | June 30, 2025 |
| GB United Kingdom | MHRA | 6 | May 15, 2026 |
CACanada· Health Canada
9 products
Uses
5 mg Hypromellose, mannitol, microcrystalline cellulose, polyethylene glycol, povidone, sodium starch glycolate, sodium stearyl fumarate, and titanium oxide. INDICATIONS AND CLINICAL USE Adults (> 18 years of age) Almotriptan (almotriptan malate) tablets are indicated for the acute treatment of migraine attacks with or without aura.
Almotriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Almotriptan have not been established for cluster headache which is present in an older, predominantly male population.
Almotriptan should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with Almotriptan, the diagnosis of migraine should be reconsidered before Almotriptan is administered to treat any subsequent attacks.
GBUnited Kingdom· MHRA
6 products
Uses
Acute treatment of the headache phase of migraine attacks with or without aura.
How to take
Drug interactions
Known interactions involving Almotriptan. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02424029 · revised March 22, 2025
- [2]MHRA (UK) · PL177801131 · revised November 14, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.